| Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. | |
| | |
MedLine Citation:
|
PMID: 22280339 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and experimental animals. The heterogeneity of cannabis-induced psychological outcomes reflects a complex network of molecular interactions between the key neurobiological substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivatives anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, respectively termed CB1 and CB2. The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concentrations of THC and other alkaloids (such as cannabidiol) within the plant itself. The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption. In addition the article presents some promising patents on cannabinoid-related agents. |
| | |
Authors:
|
Simone Tambaro; Marco Bortolato |
Related Documents
:
|
6709429 - The melkersson-rosenthal syndrome. 19539839 - Neurofibromatosis type 1. 21046879 - Mitochondrial medicine. 19932759 - Histiocytic disorders: recent insights into pathophysiology and practical guidelines. 21401819 - Expressive morphosyntax in boys with fragile x syndrome with and without autism spectru... 12675509 - Management of disorders of water metabolism in patients with pituitary tumors. 22245699 - Dimensional indicators of generalized anxiety disorder severity for dsm-v. 2510699 - The yale-brown obsessive compulsive scale. ii. validity. 16637949 - Dsm-iv diagnosed posttraumatic stress disorder in women veterans with and without milit... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Recent patents on CNS drug discovery Volume: 7 ISSN: 2212-3954 ISO Abbreviation: Recent Pat CNS Drug Discov Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-01-27 Completed Date: 2012-06-04 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101265656 Medline TA: Recent Pat CNS Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 25-40 Citation Subset: IM |
Affiliation:
|
Dept. of Pharmacology and Pharmaceutical Sciences School of Pharmacy University of Southern California, Los Angeles, CA 90089, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Anxiety Agents / pharmacology, therapeutic use* Anxiety Disorders / drug therapy* Cannabinoids / pharmacology, therapeutic use* Humans |
| Grant Support | |
ID/Acronym/Agency:
|
R21 HD070611/HD/NICHD NIH HHS; R21HD070611/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Anxiety Agents; 0/Cannabinoids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A Survey of Recent Patents on CB2 Agonists in the Management of Pain.
Next Document: Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease.